易瑞生物(300942) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥60,707,585.25, a decrease of 79.35% compared to ¥294,001,215.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥28,061,115.03, representing a decline of 124.59% from a profit of ¥114,128,972.49 in the previous year[4] - The basic earnings per share decreased to -¥0.07, down 125.00% from ¥0.28 in the same period last year[4] - The company reported a revenue of RMB 60.7076 million for Q1 2023, a decrease of 79.35% year-on-year[15] - The net profit attributable to shareholders was a loss of RMB 28.0611 million, representing a decline of 124.59% year-on-year[15] - The net profit for Q1 2023 was -28,085,394.84 CNY, compared to a net profit of 114,098,297.86 CNY in the same period last year, representing a significant decline[27] - Operating profit for Q1 2023 was -33,534,213.82 CNY, down from 139,280,317.86 CNY in Q1 2022[27] - The company reported a total comprehensive income of -28,042,280.58 CNY for Q1 2023, compared to 114,017,886.19 CNY in the same period last year[28] - Basic and diluted earnings per share for Q1 2023 were both -0.07 CNY, compared to 0.28 CNY in Q1 2022[28] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥53,990,719.10, which is a 5.50% increase in cash outflow compared to -¥51,177,229.38 in the previous year[4] - Cash and cash equivalents at the end of the first quarter were CNY 212,068,033.13, down from CNY 247,451,094.68 at the beginning of the year[21] - The total cash flow from operating activities was -53,990,719.10 CNY, compared to -51,177,229.38 CNY in the previous year, showing a slight worsening in cash flow[31] - Cash and cash equivalents at the end of Q1 2023 were 211,797,625.08 CNY, down from 303,982,289.69 CNY at the end of Q1 2022[32] - The company received 64,945,294.39 CNY in cash inflows from operating activities, a decrease from 202,641,561.46 CNY in the previous year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,202,907,829.48, a decrease of 6.20% from ¥1,282,455,601.74 at the end of the previous year[4] - As of March 31, 2023, total assets amounted to CNY 1,202,907,829.48, a decrease from CNY 1,282,455,601.74 at the beginning of the year[23] - The total liabilities decreased to CNY 262,160,828.45 from CNY 317,754,458.88[24] - Inventory decreased to CNY 83,337,947.31 from CNY 100,608,210.17, indicating a reduction in stock levels[22] - Non-current assets increased to CNY 631,158,729.22 from CNY 608,036,291.29, reflecting ongoing investments[23] Operational Highlights - The company experienced a 52.90% decrease in contract liabilities, dropping from ¥66,613,643.52 to ¥31,374,796.78, attributed to a decline in revenue from in vitro diagnostic products[7] - The company reported a significant increase in other non-current assets, which rose by 109.44% to ¥33,572,204.71 due to increased prepayments for production and R&D equipment[7] - The company plans to focus on expanding its conventional product market and developing rapid testing for food safety and animal diagnostics[15][16] - Six new patents were granted during the reporting period, including one domestic invention patent and one design patent[16] - The subsidiary, Shenzhen Ai Doctor Biotechnology Co., is enhancing its product innovation and accelerating the acquisition of new veterinary drug certificates[17] - The company has successfully launched a series of bovine early pregnancy detection products and obtained production approval for several diagnostic kits[17] - The company aims to maintain its first-mover advantage in the animal diagnostics field through product innovation and regulatory compliance[17] - The company will adjust its business focus to ensure sustainable health development in response to global market changes[16] - Shenzhen Xiupu Biotechnology Co., Ltd. was recognized as a high-tech enterprise, with the certificate number GR202244205593, valid for three years from December 19, 2022[18] - The company registered 18 new Class II medical device products domestically, including IL-6, Myo, and SAA testing kits, enhancing its product portfolio in various medical fields[19] Investment and Expenses - The company incurred financial expenses of -671,493.01 CNY in Q1 2023, a decrease from 109,037.25 CNY in the same period last year, reflecting better financial management[27] - The company’s investment income showed a loss of ¥3,718,625.02, a decline of 447.26% compared to a profit of ¥1,070,843.57 in the previous year[8] - Research and development expenses increased to 18,391,842.45 CNY in Q1 2023, up from 15,605,979.98 CNY in Q1 2022, indicating a focus on innovation[27] - Total operating costs for the first quarter were CNY 94,325,423.68, compared to CNY 155,220,845.49 in the previous year[25] - The company reported a gross profit margin decline, with operating costs at CNY 45,522,665.69 against the revenue of CNY 60,707,585.25[25] - Investment activities generated a net cash flow of 23,962,684.77 CNY in Q1 2023, compared to 15,956,035.85 CNY in Q1 2022, indicating improved investment performance[31]